Overview

A Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects

Status:
Completed

Trial end date:
2017-07-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the bioequivalence of a 200 mg single dose Lacosamide (LCM) intravenous (iv) solution with a 200 mg single dose LCM oral tablet in healthy Chinese male subjects.

Phase:

Phase 1

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.

Treatments:

Lacosamide
Pharmaceutical Solutions